Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 14/20 | 0.50 |
| ▸ | CCKAR | P32238 | 6/20 | 0.49 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | USP8 | P40818 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887691 | 1.00 | CCKBR (0.50) | CCKBRCCKARSLC40A1PDE2AUSP2 | |
| SCHEMBL1884672 | 0.93 | CCKBR (0.57) | CCKBRCCKARPKLR | |
| SCHEMBL1884675 | 0.93 | CCKBR (0.57) | CCKBRCCKARPKLR | |
| SCHEMBL31616335 | 0.89 | CCKBR (0.61) | CCKBRCCKAR | |
| SCHEMBL1885769 | 0.89 | CCKBR (0.61) | CCKBRCCKAR | |
| SCHEMBL1889837 | 0.89 | CCKBR (0.53) | CCKBRCCKAR | |
| SCHEMBL1885772 | 0.89 | CCKBR (0.61) | CCKBRCCKAR | |
| SCHEMBL31618389 | 0.89 | CCKBR (0.61) | CCKBRCCKAR | |
| SCHEMBL1886233 | 0.89 | CCKBR (0.61) | CCKBRCCKAR | |
| SCHEMBL1889841 | 0.89 | CCKBR (0.53) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651621-B1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | claimed |
| US-7304051-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | claimed |
| CN-1863781-A | 2- (quinoxalin-5-ylsulfonamido) -benzamide compounds as cholecystokinin 2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-15 | — | — | CN | claimed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | claimed |
| US-7947833-B2 | methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds CCK2 modulators are disclosed by sulfonylation | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947833-B2 | methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds CCK2 modulators are disclosed by sulfonylation | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947833-B2 | methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds CCK2 modulators are disclosed by sulfonylation | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7563895-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-21 | — | — | US | disclosed |
| US-7563895-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-21 | — | — | US | disclosed |
| US-7563895-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-21 | — | — | US | disclosed |
| EP-1651621-B1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | disclosed |
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20020103317-A1 | Polymeric compositions for forming optical waveguides; optical waveguides formed therefrom; and methods for making same | SUMITOMO BAKELITE CO., LTD. (JP) | 2002-08-01 | — | — | US | disclosed |
| US-6350832-B1 | CATALYTIC COSSLINKING POLYMER OF POLYCYCLOOLEFIN MONOMER, MOLDING AND SHAPING IN THE PRESENCE OF GROUP 10 TRANSITION METAL AND ANION | THE B. F. GOODRICH COMPANY | 2002-02-26 | — | — | US | disclosed |
| WO-2002010810-A2 | OPTICAL WAVEGUIDES AND METHODS FOR MAKING THE SAME | GOODRICH CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002010231-A2 | POLYMERIC COMPOSITIONS FOR FORMING OPTICAL WAVEGUIDES; OPTICAL WAVEGUIDES FORMED THEREFROM; AND METHODS FOR MAKING SAME | GOODRICH CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-1155057-A1 | IN MOLD ADDITION POLYMERIZATION OF NORBORNENE-TYPE MONOMERS USING GROUP 10 METAL COMPLEXES | The B.F.Goodrich Co. (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1034196-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | THE B.F. GOODRICH COMPANY (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-2000034344-A1 | IN MOLD ADDITION POLYMERIZATION OF NORBORNENE-TYPE MONOMERS USING GROUP 10 METAL COMPLEXES | THE B.F.GOODRICH COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000020472-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | THE B.F. GOODRICH COMPANY (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | CCKAR, CCKBR, GIPR | CCKBR 2/4885CCKAR 1/4885SLC40A1 3590/4885 |
| US-20050038032-A1 | Quinoxaline compounds | CCKAR, CCKBR, GIPR | CCKBR 2/4885CCKAR 1/4885SLC40A1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.